SCHEMBL6563501

SCHEMBL6563501

CC(C)(C)OC(=O)NCCNS(=O)(=O)c1c(Cl)ccc(N)c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.42
CXCR1 P25024 1/20 0.42
CA1 P00915 10/20 0.41
CA2 P00918 9/20 0.41
CA12 O43570 6/20 0.41
CA9 Q16790 5/20 0.41
ALOX5AP P20292 1/20 0.41
FEN1 P39748 1/20 0.41
MALT1 Q9UDY8 1/20 0.38
IDO1 P14902 2/20 0.38
BCHE P06276 1/20 0.37
NQO2 P16083 1/20 0.37
STK17B O94768 1/20 0.37
STK17A Q9UEE5 1/20 0.37
CA7 P43166 1/20 0.37
CA14 Q9ULX7 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
GLA P06280 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6563429 0.93 CXCR1 (0.45) CXCR2CXCR1CA1CA2CA12
SCHEMBL6563381 0.83 MAPK1 (0.43) CXCR2CXCR1CA1CA2CA12
SCHEMBL6565711 0.80 ALDH1A1 (0.56) CXCR2CXCR1CA1CA2ALDH1A1
SCHEMBL6563973 0.79 CXCR2 (0.48) CXCR2CXCR1MALT1
SCHEMBL6564085 0.78 CXCR2 (0.59) CXCR2CXCR1
SCHEMBL6565726 0.78 CA12 (0.46) CXCR2CA1CA2CA12CA9
SCHEMBL4587033 0.77 CXCR2 (0.58) CXCR2CXCR1
SCHEMBL6564237 0.77 MAPK1 (0.43) CXCR2CXCR1CA1CA2CA12
SCHEMBL6565584 0.77 CXCR2 (0.56) CXCR2ALDH1A1MAPTHPGDHTT
SCHEMBL6564213 0.77 CXCR1 (0.42) CXCR2CXCR1CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161232-B1 HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-03-24 EP disclosed
US-20030109527-A1 Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-06-12 US disclosed
US-6500863-B1 INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2002-12-31 US disclosed
EP-1161232-A4 HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-09-18 EP disclosed
CN-1334726-A Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists SMITHKLINE BEECHAM CORP (US) 2002-02-06 CN disclosed
EP-1161232-A1 HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2001-12-12 EP disclosed
WO-2000035442-A1 HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109527-A1 Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists CXCL8, CCR8, IL18 CXCR2 26/4885CXCR1 18/4885CA1 4428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.